Accessibility Menu
ZyVersa Therapeutics logo

ZyVersa Therapeutics(OTC) ZVSA

Current Price$0.11
Market Cap$955.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-20%
1 Month-28%
ZyVersa Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.122026-07-22
ZyVersa Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.23%USD 0.132026-07-15
1 month-28.48%USD 0.172026-06-22
3 month-37.89%USD 0.192026-04-23
Year to date-11.68%USD 0.132025-12-31
1 year-20%USD 0.152025-07-22
3 year-99.83%USD 69.442023-07-21
Since inception-100%USD 3,447.502022-02-10

ZyVersa Therapeutics Financials at a Glance

Market Cap

$955.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$24.49M

EPS (TTM)

-$3.32

P/E Ratio

-0.04

Dividend

$0.00

Beta (Volatility)

0.34 (Low)

Price

$0.11

Volume

1,704

Open

$0.12

Previous Close

$0.11

Daily Range

$0.11 - $0.13

52-Week Range

$0.10 - $0.30

Estimated Earnings Date

Aug 13, 2026

ZVSA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ZyVersa Therapeutics

ZyVersa develops drugs for kidney and inflammatory diseases. Its products aim to help people with chronic health conditions. The company focuses on treatments where few options exist today.

Lab Bench to Bedside: ZyVersa’s Main Offerings

  • VAR 200 (Renal Disease Drug): Injectable treatment in clinical trials for kidney diseases like focal segmental glomerulosclerosis (FSGS); 0% of revenue as of 2025.
  • IC 100 (Inflammatory Disease Antibody): Preclinical antibody therapy targeting inflammation in conditions linked to obesity and neurodegenerative diseases; 0% of revenue as of 2025.
  • Drug Development Services: Research and development for new therapies; no commercial sales to date.

Growth Spurts and Stumbles: Expansion Moves

  • Planning Phase 2a trial for VAR 200 in FSGS and Alport syndrome in Q2-2026.
  • IND submission for IC 100 targeted for Q4-2026, with Phase 1 trial to follow.
  • Delisted from Nasdaq in October 2025; now trades on OTCQB.
  • Raised $1.0 million via convertible notes in February 2026 to fund operations.
  • Expanding intellectual property portfolio and seeking orphan drug status for lead products.

Why ZyVersa Is a Bit Different

ZyVersa holds exclusive licenses for its drug platforms, discovered at the University of Miami. Its therapies target disease pathways not addressed by other drugs, aiming for multiple uses per product. The company relies on third-party vendors for research and manufacturing, keeping its team small and focused.

Five Things You Need to Know

  • Reported $0 revenue for 2023, 2024, and 2025; no product sales yet.
  • Net loss was $24.95 million in 2025, up 165.1% from 2024.
  • Operating expenses reached $25.49 million in 2025, up 179% year-over-year.
  • Cash was $0.1 million at end of 2025; working capital deficit was $12.4 million.
  • Delisted from Nasdaq in 2025; now trades on OTCQB with reduced liquidity.

Bottom Line

ZyVersa remains a pre-commercial biotech focused on kidney and inflammatory disease drugs. The company faces funding challenges but continues to advance its clinical pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6

CEO

Stephen C. Glover

Website

www.zyversa.com

Headquarters

Weston, FL 33326, US

ZVSA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.79%

Return on Capital

N/A

Return on Assets

-3.30%

Earnings Yield

-25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$955.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.10M

Volume

1.70K

Avg. Volume

13.48K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$2.14B

EBITDA

-$24.69M

Operating Cash Flow

-$2.62B

Capital Expenditure

$0.00

Free Cash Flow

-$2.62B

Cash & ST Invst.

$302.66M

Total Debt

$1.20B

ZyVersa Therapeutics Performance Analysis

ZyVersa Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
ZyVersa Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
ZyVersa Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -930.25435.7%
20232023-12-31USD -1,089.6717.1%
20242024-12-31USD -8.48-99.2%
20252025-12-31USD -4.18-50.7%
ZyVersa Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3037.0%
Q32025-09-30-456.5%
Q42025-12-3196.7%
Q12026-03-31-162.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$955.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$159.22K

N/A

Employees

6

N/A

Net Income

-$1.79M

+20.5%

EBITDA

-$1.66M

+26.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$302.66M

+18680.9%

Total Debt

$1.20B

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.20B

N/A

Return on Assets

-3.30%

N/A

Return on Invested Capital

-15.13%

N/A

Free Cash Flow

-$799.12M

+54.9%

Operating Cash Flow

-$799.12M

+54.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLXNSilexion Therapeutics Ltd.
$2.38-5.56%
ENVBEnveric Biosciences, Inc.
$1.32-1.49%
WORXSCWorx Corp.
$0.55-3.93%
HEPAHepion Pharmaceuticals, Inc.
$0.05-14.82%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
NOKNokia
$9.73-0.05%
AALAmerican Airlines Group
$13.56-0.08%
TAT&T
$22.96-0.00%

Questions About ZVSA

What is the current price of ZyVersa Therapeutics?

ZyVersa Therapeutics is trading at $0.11 per share.

What is the 52-week range for ZyVersa Therapeutics?

Over the past 52 weeks, ZyVersa Therapeutics has traded between $0.10 and $0.30.

How much debt does ZyVersa Therapeutics have?

As of the most recent reporting period, ZyVersa Therapeutics reported total debt of $1.20M.

How much cash does ZyVersa Therapeutics have on hand?

ZyVersa Therapeutics reported $302.66K in cash and cash equivalents in its most recent financial results.

What is ZyVersa Therapeutics’s dividend yield?

ZyVersa Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services